Citation Impact
Citing Papers
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
2000 Standout
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
2016
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
1998
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
2001
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer
2003
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
2008
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
2010
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
1998
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
1994
Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy
2001
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
1999
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer
1994
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
1995
Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
2004
HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
2000
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
2001
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
2005
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
c- erb B-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1α Dependent
2004
Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
2001
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
2000
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
1999
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
1999
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer
1997
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
1995
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
1997
Cancer statistics, 2020
2020 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Prognostic Factors in Breast Cancer
2000
EGFR Antagonists in Cancer Treatment
2008 Standout
Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the radiation therapy oncology group study 81-17
1990
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
2004 Standout
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
1994
Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement
1989
Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: Increased concentration of CD33 antigen predicts poor outcome—A report from the childrens cancer study group
1992
The biology and management of non-small cell lung cancer
2018 StandoutNature
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
2000
Regimen-related toxicity in patients undergoing bone marrow transplantation.
1988 StandoutNobel
HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
2004
Lung Cancer
2008 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
1997
The changing landscape of atherosclerosis
2021 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
1998
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
1992
The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinoma
2000
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
2019
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
2005
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Pathological prognostic factors in breast cancer
1999 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
2005
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
1990
Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
2001
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Genetic alterations in breast cancer
1995
Cancer immunotherapy comes of age
2011 StandoutNature
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
2008
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Pancreatic Cancer
2010 Standout
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk
2020
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
1989 StandoutNobel
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
1997
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
The cancer genome
2009 StandoutNature
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
2004
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study
1987
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
2006
Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables
2001
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
1987 StandoutNobel
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia
1984
DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?
2001
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?
2001
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer
2006
14-3-3σ Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non–Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group
2005
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
1999
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Works of RD Gelber being referenced
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
1992
Preoperative systemic treatment: prediction of responsiveness
2003
c-erbB-2 protein expression in node negative breast cancer
1990
Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy
1997
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
2000
The Treatment of Acute Myelogenous Leukemia in Children and Adults: VAPA Update
1983
Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708)
2010
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update
1983
P118 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 2-06/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC)
2007
Analysis of survival by tumor response.
1983
The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy
1998